Genmab — Februar 2019
-
Måske derfor at vi fik tilbagefald.
-
Genmab og C20 faldt synkront.
-
-
hæh - sjovt som den økonomiske verden kan vendes på hovedet i løbet af ingen tid. Var de tal kommet for 1 måned siden, var aktierne steget som følge af at vi så ikke ville se flere rentestigninger. I dag forventer vi ikke flere stigninger i renten - så derfor falder vi...
-
Tak Pauly. Det er et pænt foto.
-
Ja...Det er betryggende.
-
http://www.evaluate.com/vantage/articles/data-insights/other-data/sellsides-mid-term-forecast-sunny-few-hints-rain EvaluatePharma’s current consensus forecasts for 2022 vs end of 2017 , undortunate spot for Dara in that list
-
hmm - could be a result of the solids
-
BCMA directed CART in #myeloma. Impressive initial responses but not very durable even in very good responders. https://twitter.com/graham74GC/status/1096026439449743360
-
I don't want to start another 'solid' discussion, but, uhm, should i read anything into the fact that Rachel is retweeting this "...…the first trials with INCB001158 are in solid tumors. Will be interesting to see, IF this Multiple Myeloma trial works with Daratumumab, if INCY will try them together in solids also."
https://twitter.com/EgidiusLambrech/status/1096006399191064576
Men det vidste du nok
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind